Manvi Biopharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 07-07-2024
- Paid Up Capital ₹ 3.33 M
as on 07-07-2024
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.28 M
as on 07-07-2024
- Satisfied Charges ₹ 3.40 Cr
as on 07-07-2024
- Revenue 252.16%
(FY 2021)
- Profit 722.08%
(FY 2021)
- Ebitda 1545.10%
(FY 2021)
- Net Worth 3970.26%
(FY 2021)
- Total Assets 150.14%
(FY 2021)
About Manvi Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.33 M.
The company currently has active open charges totaling ₹1.28 M. The company has closed loans amounting to ₹3.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramakanth Katta, Gnana Gandavarapu, Varunkumarreddy Koduru, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC127913
- Company No.
127913
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Oct 2018
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Manvi Biopharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramakanth Katta  | Director | 21-Dec-2020 | Current |
| Gnana Gandavarapu | Director | 20-Feb-2020 | Current |
| Varunkumarreddy Koduru | Director | 10-May-2019 | Current |
| Nagamani Kaperla | Director | 26-Oct-2018 | Current |
Financial Performance of Manvi Biopharma.
Manvi Biopharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 252.16% increase. The company also saw a substantial improvement in profitability, with a 722.08% increase in profit. The company's net worth Soared by an impressive increase of 3970.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manvi Biopharma?
In 2021, Manvi Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fugen Laboratories Private LimitedActive 19 years 10 monthsRamakanth Katta, Varunkumarreddy Koduru and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The South Indian Bank Limited Creation Date: 06 Mar 2020 | ₹1.28 M | Open |
The South Indian Bank Limited Creation Date: 27 Dec 2019 | ₹3.40 Cr | Satisfied |
How Many Employees Work at Manvi Biopharma?
Manvi Biopharma has a workforce of 49 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manvi Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manvi Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
